chronic kidney disease • hemodialysis • metabolic bone disease • polycystic kidney disease • anemia
My research focuses on involving progression of chronic kidney disease, the anemia of chronic kidney disease, the complications of mineral metabolism in chronic kidney disease, factors leading to anemia in chronic kidney disease and measures to correct anemia, iron deficiencies and other causes of anemia. In addition, we participate in research on polycystic kidney disease including parameters of progression as well as the use of Tolvalptan to block the effect of vasopressin in the cysts of PKD. With respect to anemia of CKD, we have been involved in the use of several products to stimulate the production of an increase in hemoglobin.
Allen D, Badro V, D'Enyer-Willis L, MacDonald M, Paré A, Hutchinson T, Barré P, Beauchemin R, Bocti H, Broadbent A, Cohen SR. Fragmented care and whole-person illness: Decision-making for people with chronic, end-stage kidney disease. 2014. Chronic Illn. 2015 Mar;11(1):44-55. PMID: 25475415.
Alam A, Palumbo A, Mucsi I, Barre PE, Sniderman A. Elevated troponin I levels but not low grade chronic inflammation is associated with a cardiospecific mortality in stable hemodialysis patients. BMC Nephrology 2013,14:247. PMID: 24206774.
Torres VE et al. Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease. N Engl J Med 2012: 367:2407-18. PMID: 23121377.
Baigent C, Landray MJ, Emherson J et al. on behalf of SHARP investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomized placebo-controlled trial. Lancet Published online June 9, 2011. DOI:10.1016/50140-6736(11)60739-3. Lancet 2011;377:2181-2191. PMID: 21663949.
Hemmelgarn BR, Moist LM, Lok CE, Tonelli M, Manns BJ, Holden RM, Leblanc M, Faris P, Barre P, Zhang J, Scott-Douglas N. Prevention of Dialysis Catheter Malfunction with rt-PA versus Heparin. N Engl J Med 2011;364:303-312. PMID: 21268722.